Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
Medical Oncology Department, National Institute of Oncology, Rabat, Morocco.
Ibrahim
I
Elghissassi
Medical Oncology Department, National Institute of Oncology, Rabat, Morocco.
Saber
S
Boutayeb
Medical Oncology Department, National Institute of Oncology, Rabat, Morocco.
Hanane
H
Inrhaoun
Medical Oncology Department, National Institute of Oncology, Rabat, Morocco.
Hind
H
Mrabti
Medical Oncology Department, National Institute of Oncology, Rabat, Morocco.
Hassan
H
Errihani